1. Signaling Pathways
  2. MAPK/ERK Pathway
  3. p38 MAPK
  4. p38 MAPK Isoform

p38 MAPK


p38 MAPK Related Products (87):

Cat. No. Product Name Effect Purity
  • HY-10256
    Inhibitor 99.96%
    Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively.
  • HY-10320
    Inhibitor 99.98%
    Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC50 for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM.
  • HY-N0168
    Modulator 99.16%
    Hesperetin is a natural flavanone, and acts as a potent and broad-spectrum inhibitor against human UGT activity.
  • HY-10256A
    Adezmapimod hydrochloride
    Inhibitor 99.71%
    Adezmapimod (SB 203580) hydrochloride is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively.
  • HY-10578
    PD 169316
    Inhibitor 98.0%
    PD 169316 is a potent, cell-permeable and selective p38 MAP kinase inhibitor, with IC50 of 89 nM.
  • HY-10402
    Inhibitor 99.96%
    Losmapimod (GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pKis of 8.1 and 7.6 for p38α and p38β, respectively.
  • HY-107427
    Inhibitor 99.93%
    PF-3644022 is a potent, selective, orally active and ATP-competitive MAPKAPK2 (MK2) inhibitor with an IC50 of 5.2 nM and a Ki of 3 nM.
  • HY-127090
    Muramyl dipeptide
    Activator ≥98.0%
    Muramyl dipeptide (MDP) is a synthetic immunoreactive peptide, consisting of N-acetyl muramic acid attached to a short amino acid chain of L-Ala-D-isoGln.
  • HY-11068
    SB 239063
    Inhibitor 99.80%
    SB 239063 is a potent, selective and orally active p38 MAPK inhibitor, exhibits an IC50 of 44 nM for recombinant purified human p38α, with equipotent inhibitory activity against p38α and p38β.
  • HY-10403
    Inhibitor 98.94%
    PH-797804 is a ATP-competitive, selective p38α/p38β inhibitor (IC50=26 nM and Ki=5.8 nM for p38α; Ki=40 nM for p38β) and does not inhibit JNK2.
  • HY-15509A
    Semapimod tetrahydrochloride
    Semapimod tetrahydrochloride (CNI-1493), an inhibitor of proinflammatory cytokine production, can inhibit TNF-α, IL-1β, and IL-6.
  • HY-16782
    Inhibitor 99.93%
    Pexmetinib is a potent Tie-2 and p38 MAPK dual inhibitor, with IC50s of 1 nM, 35 nM and 26 nM for Tie-2, p38α and p38β, respectively, and can be used in the research of acute myeloid leukemia.
  • HY-10401
    Inhibitor 99.44%
    VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β.
  • HY-19900
    Inhibitor 98.38%
    ITX5061 is a type II inhibitor of p38 MAPK and also an antagonist of scavenger receptor B1 (SR-B1).
  • HY-N2406
    Dihydrocaffeic acid
    Inhibitor ≥98.0%
    Dihydrocaffeic acid is a microbial metabolite of flavonoids, reduces phosphorylation of MAPK p38 and prevent UVB-induced skin damage.
  • HY-N0235
    Inhibitor 98.13%
    Bakuchiol is a phytoestrogen isolated from the seeds of Psoralea corylifolia L; has anti-tumor effects.
  • HY-B0736A
    Sertaconazole nitrate
    Activator 99.58%
    Sertaconazole nitrate (FI7056) is a broad-spectrum topical antifungal agent, exhibits anti-inflammatory activity via activation of a p38-COX-2-PGE2 pathway.
  • HY-N0188
    Inhibitor 99.19%
    Esculin, a fluorescent coumarin glucoside, is an active ingredient of ash bark.
  • HY-N3584
    Paris saponin VII
    Inhibitor 99.13%
    Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii.
  • HY-W007355
    Activator 99.95%
    Skatole is produced by intestinal bacteria, regulates intestinal epithelial cellular functions through activating aryl hydrocarbon receptors and p38.